Moberg Pharma interim report January - March 2017
CONTINUED STRONG GROWTH IN EBITDAFIRST QUARTER (JAN–MAR 2017) · Net revenue SEK 104.6 million (69.5) · EBITDA SEK 16.7 million (3.4) · EBITDA for commercial operations SEK 21.0 million (7.0) · Operating profit (EBIT) SEK 6.9 million (0.5) · Profit after tax SEK -3.0 million (-5.6) · Earnings per share SEK -0.17 (-0.40) · Operating cash flow per share SEK -0.17 (-0.25) SIGNIFICANT EVENTS DURING THE FIRST QUARTER · Nationwide launch in Japan for Zanmira® Nail (Kerasal Nail®) · Additional distribution for New Skin® Spray at Walmart and Walgreens · The